Ellen Cooper
Known title: EVP & CIOCIK: 0001555614
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Lincoln Financial Closes $6.3B Talcott Reinsurance Deal. Lincoln Financial Group completed a $6.3 billion reinsurance transaction with Talcott, a significant move to manage risk and optimize capital. This deal occurs as the company prepares to report its third-quarter results on November 5. The stock is currently trading near its 52-week low, reflecting broader market caution despite the company's high dividend yield.
Transaction History
| COR | ▲ Buy | Grant | 97 | $30K | 7/31/2026 | View on chart |
| COR | ▲ Buy | Grant | 99 | $30K | 5/1/2026 | View on chart |
| COR | ▲ Buy | Grant | 557 | $200K | 3/5/2026 | View on chart |
| LNC | ▼ Sell | Tax Withholding | 12,316 | $494K | 2/19/2026 | View on chart |
| LNC | ▲ Buy | Grant | 109,227 | $0 | 2/19/2026 | View on chart |
| LNC | ▲ Buy | Grant | 189,295 | $0 | 2/19/2026 | View on chart |
| LNC | ▼ Sell | Tax Withholding | 80,413 | $3.2M | 2/19/2026 | View on chart |
| LNC | ▲ Buy | Grant | 28,992 | $0 | 2/19/2026 | View on chart |
| LNC | ▼ Sell | Tax Withholding | 18,669 | $763K | 2/15/2026 | View on chart |
| COR | ▲ Buy | Grant | 69 | $25K | 1/30/2026 | View on chart |
| COR | ▲ Buy | Grant | 66 | $24K | 1/30/2026 | View on chart |
| LNC | ▲ Buy | Option Exercise | 38,891 | $1.4M | 11/26/2025 | View on chart |
| LNC | ▼ Sell | Tax Withholding | 35,726 | $1.5M | 11/26/2025 | View on chart |
| LNC | ▼ Sell | Tax Withholding | 4,401 | $178K | 11/24/2025 | View on chart |
| LNC | ▼ Sell | Tax Withholding | 3,781 | $122K | 5/26/2025 | View on chart |
| LNC | ▲ Buy | Grant | 92,143 | $0 | 2/19/2025 | View on chart |
| LNC | ▲ Buy | Grant | 108,012 | $0 | 2/19/2025 | View on chart |
| LNC | ▼ Sell | Tax Withholding | 3,824 | $149K | 2/16/2025 | View on chart |
| LNC | ▼ Sell | Tax Withholding | 962 | $28K | 5/7/2024 | View on chart |
| LNC | ▲ Buy | Grant | 128,985 | $0 | 2/21/2024 | View on chart |
| LNC | ▼ Sell | Tax Withholding | 3,747 | $102K | 2/18/2024 | View on chart |
| LNC | ▼ Sell | Tax Withholding | 2,759 | $93K | 2/19/2023 | View on chart |
| LNC | ▲ Buy | Grant | 43,856 | $0 | 2/15/2023 | View on chart |
| LNC | ▲ Buy | Grant | 7,480 | $0 | 5/26/2022 | View on chart |
| LNC | ▼ Sell | Tax Withholding | 3,636 | $251K | 2/27/2022 | View on chart |
| LNC | ▲ Buy | Grant | 14,184 | $0 | 2/16/2022 | View on chart |
| LNC | ▼ Sell | Tax Withholding | 4,024 | $296K | 2/16/2022 | View on chart |
| LNC | ▲ Buy | Grant | 11,784 | $0 | 2/16/2022 | View on chart |
| LNC | ▼ Sell | Tax Withholding | 130 | $9K | 11/18/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cencora Valuation and AI Impact: Analysts Debate Growth Prospects
Recent analyses debate whether Cencora is undervalued or if its raised guidance is already priced in, as the stock trades near its 52-week high and average analyst target. Other reports suggest the company's distribution model could benefit more from AI disruption than certain telehealth competitors. The stock is also compared to major pharmaceutical companies like AbbVie and Eli Lilly as market participants assess the healthcare sector.
Cencora Valuation and AI Impact: Analysts Debate Growth Prospects. Recent analyses debate whether Cencora is undervalued or if its raised guidance is already priced in, as the stock trades near its 52-week high and average analyst target. Other reports suggest the company's distribution model could benefit more from AI disruption than certain telehealth competitors. The stock is also compared to major pharmaceutical companies like AbbVie and Eli Lilly as market participants assess the healthcare sector.